Study guide
13.6 Trial Registration, Results Transparency & Communicating Results to Participants
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
13.6 Trial Registration, Results Transparency & Communicating Results to Participants
Key Takeaways Explain This Topic AI
ICH E6(R3) Principle 9.6 makes transparency a GCP principle: timely registration on publicly accessible databases and public posting of trial results.
The 2024 Declaration of Helsinki paragraph 35 requires registration in a publicly accessible database before recruitment of the first participant.
Declaration of Helsinki paragraph 36 obliges researchers to make results publicly available, and states that negative and inconclusive as well as positive results must be published.
ICH E6(R3) Principle 9.6 adds that communicating results to participants should be considered, and that such communication should be objective and non-promotional.
Selective reporting of favourable outcomes is a research integrity failure, and a registered protocol with pre-specified endpoints is the control that makes it detectable.
Last updated: August 2026
Trial Registration, Results Transparency & Communicating Results to Participants
Quick Reference: ICH E6(R3) Principle 9.6 states that "the transparency of clinical trials includes timely registration on publicly accessible and recognised databases and the public posting of clinical trial results. Communicating trial results to participants should be considered. Such communication should be objective and non-promotional." Transparency is no longer a publication-ethics footnote — it is one of the eleven principles.
Why this is new, and why it is tested
E6(R2) contained no transparency principle. Registration and results posting lived in journal policy, national law and the Declaration of Helsinki, but not in GCP itself. E6(R3) changed that, which makes transparency exactly the kind of topic that generates fresh exam items: an experienced candidate reasoning from E6(R2) instincts will get it wrong.
The obligation also appears in the other reference document ACRP names — the Declaration of Helsinki , revised by the World Medical Association in October 2024 .
Registration: before the first participant
- Source Requirement
- ICH E6(R3) Principle 9.6 Timely registration on publicly accessible and recognised databases
Declaration of Helsinki (2024), paragraph 35 "Medical research involving human participants must be registered in a publicly accessible database before recruitment of the first participant."
Read the Helsinki wording carefully: the deadline is before recruitment of the first participant , not before the first participant is randomised, not before enrolment closes, and not at publication.
Why prospective registration matters
Registration before recruitment creates a public, timestamped record of what the trial said it would measure before anyone knew how it would turn out. That single fact defeats three distinct failure modes:
Publication bias — a trial that exists in a registry cannot silently disappear when its results disappoint.
Outcome switching — promoting a secondary endpoint to primary after seeing the data becomes visible, because the registered entry names the original primary endpoint.
Duplicate or wasteful research — investigators and funders can see what is already under way.
- What a registration entry contains
- Sponsor, funder and responsible party
- Condition, intervention and comparator
- Study design, phase, allocation and masking
- Primary and secondary outcome measures , with time frames
- Key eligibility criteria
- Target sample size
- Recruitment status and locations
- Contact information
Exam Watchout: Registration is normally a sponsor responsibility, but the site is affected by it. Participants and their treating physicians consult registries, the registry record must match the approved protocol, and a mismatch between the registered primary endpoint and the protocol is a finding. Where a substantial amendment changes an endpoint or the design, the registry record must be updated , not left as first posted.
Results posting: including the results nobody wanted
- Source Requirement
- ICH E6(R3) Principle 9.6 Public posting of clinical trial results
Declaration of Helsinki (2024), paragraph 36 Researchers have a duty to make results publicly available; "negative and inconclusive as well as positive results must be published or otherwise made publicly available."
The phrase "negative and inconclusive as well as positive" is the examinable part. The ethical argument is direct: participants accepted risk and burden on the understanding that their contribution would add to knowledge. Suppressing an unfavourable result breaks that bargain and, worse, leaves clinicians with a systematically distorted evidence base — the treatment looks better than it is because only the flattering trials were published.
Selective reporting as an integrity failure
Publishing only favourable outcomes, or reframing the analysis after seeing the data, is a research integrity failure of the same family as those in section 7.4. The controls are structural rather than moral:
- Control What it prevents
- Prospective registration with named primary endpoint Outcome switching
- Statistical analysis plan finalised before database lock and unblinding Analysis chosen to fit the result
- Pre-specified handling of missing data and of the analysis populations Post hoc population selection
- Clinical study report covering all pre-specified endpoints Quiet omission of endpoints that failed
Publication policy in the protocol — Declaration of Helsinki paragraph 22 places funding and conflicts in the protocol; publication arrangements belong there too Sponsor veto over unfavourable findings
Exam Watchout: A clinical trial agreement clause permitting the sponsor to delay publication for a defined, reasonable period to protect intellectual property is normal and acceptable. A clause permitting the sponsor to suppress publication, or to publish only if results are favourable, is not, and an investigator should not sign it.
Communicating results to participants
This is the newest and least familiar element. E6(R3) Principle 9.6 says communicating results to participants should be considered , and that any such communication "should be objective and non-promotional." ECO task statement 41 states it as an activity: "Inform study participants of study results, in accordance with regulatory requirements."
Note the calibration precisely, because the exam will test it: this is "should be considered" — a deliberate obligation to think about it and plan for it — not an absolute requirement to disseminate individually in every trial. What is not optional is the manner : objective and non-promotional.
Doing it well
Element Good practice
Plan it in advance Describe in the protocol and consent form whether and how results will be shared; participants should not be surprised either way
Timing After database lock and analysis, coordinated with the primary publication or posting
Format A plain-language summary — no promotional adjectives, no unqualified claims of benefit, plain terms for endpoints
Content What the trial asked, what was found overall, what it means, and the honest limitations, including when results were negative or inconclusive
Aggregate, not individual Trial-level results, not a participant's own treatment assignment or data, unless the protocol specifically provides for individual return
- Approval IRB/IEC review of the participant-facing summary before distribution
- Two distinct things participants ask for
"How did the trial turn out?" — aggregate results. Answered by the planned summary once available.
"Which arm was I in?" — individual unblinding. This is not released on request during the trial, and after the trial only per the protocol's provisions. A coordinator should never disclose arm assignment informally, and a participant asking mid-trial should be told, kindly, that the answer would compromise the trial and will be available in line with the plan described at consent.
Where a trial generates a clinically actionable individual finding — an incidental imaging finding, a genetic result the consent covered — return of that specific result follows the protocol's own pathway, which is separate from results dissemination.
Realistic exam scenario
Scenario: A three-year trial completes. The primary endpoint was not met; a secondary endpoint reached nominal significance. The sponsor's publication committee proposes to submit a manuscript titled around the secondary endpoint, to update the registry entry so the secondary endpoint is listed first, and to send participants a letter thanking them and stating that "the study showed encouraging benefits." A coordinator is asked to post the letter to her site's 42 participants.
Evaluation — four separate failures:
Reframing the manuscript around the secondary endpoint is outcome switching. The registered and protocol-specified primary endpoint was not met, and that must be reported as the trial's principal finding.
Retrospectively reordering the registry entry compounds it. Registry records are amended to reflect approved protocol changes made prospectively, not to reflect what the data later favoured.
"Encouraging benefits" is promotional , and E6(R3) Principle 9.6 requires participant communication to be objective and non-promotional . It is also inaccurate, since the trial's primary question was answered in the negative.
The letter has not been through IRB/IEC review and was not described to participants at consent.
Correct actions: the coordinator should decline to distribute the letter as drafted and escalate to the sponsor and the principal investigator. The primary endpoint result must be reported publicly regardless of its direction — Declaration of Helsinki paragraph 36 requires negative and inconclusive results to be made publicly available. The registry entry should reflect the endpoints as prospectively specified. Any participant-facing summary should be rewritten in plain, objective language stating that the trial did not meet its primary endpoint, describing the secondary finding with appropriate caution about its exploratory status, and thanking participants for a contribution that is valuable precisely because it produced a reliable answer. The revised summary goes to the IRB/IEC before it goes to participants.